Clinical Trial Update: Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

Update on a phase 2/3 trial of irinotecan-eluting beads (DEBIRI) for colorectal cancer with liver metastases; current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• DEBIRI (irinotecan-eluting bead) (irinotecan-eluting bead)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Colon Cancer Liver Metastasis | Phase 2, Phase 3 | Status: UNKNOWN